According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
ArQule (NASDAQ:ARQL) opened at 1.64 on Tuesday. The company’s 50-day moving average is $1.57 and its 200-day moving average is $1.64. ArQule has a 52-week low of $1.37 and a 52-week high of $2.65. The firm’s market capitalization is $116.61 million.
ArQule (NASDAQ:ARQL) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. ArQule had a negative net margin of 197.25% and a negative return on equity of 44.89%. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.13 million. During the same period in the prior year, the firm earned ($0.06) EPS. The firm’s revenue for the quarter was down 64.3% on a year-over-year basis. On average, analysts predict that ArQule will post ($0.33) EPS for the current year.
Several large investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC increased its stake in shares of ArQule by 44.6% in the first quarter. Nantahala Capital Management LLC now owns 8,543,652 shares of the company’s stock worth $13,670,000 after buying an additional 2,635,530 shares in the last quarter. BVF Inc. IL increased its stake in shares of ArQule by 15.9% in the first quarter. BVF Inc. IL now owns 7,893,324 shares of the company’s stock worth $12,629,000 after buying an additional 1,083,481 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of ArQule by 10.6% in the second quarter. Vanguard Group Inc. now owns 2,960,487 shares of the company’s stock worth $5,625,000 after buying an additional 282,734 shares in the last quarter. Sabby Management LLC purchased a new stake in shares of ArQule during the first quarter worth approximately $160,000. Finally, BlackRock Fund Advisors increased its stake in shares of ArQule by 11.3% in the second quarter. BlackRock Fund Advisors now owns 162,541 shares of the company’s stock worth $309,000 after buying an additional 16,467 shares in the last quarter. 58.16% of the stock is currently owned by institutional investors.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.